Verrica Pharmaceuticals (NASDAQ:VRCA) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Verrica Pharmaceuticals (NASDAQ:VRCA) from a strong sell rating to a sell rating in a research note released on Saturday,Wall Street Zen reports.

Several other analysts have also commented on VRCA. Weiss Ratings reissued a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, July 15th. Lake Street Capital initiated coverage on shares of Verrica Pharmaceuticals in a research report on Thursday, August 27th. They issued a “buy” rating and a $9.00 price target on the stock. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $12.67.

Verrica Pharmaceuticals Price Performance

Shares of NASDAQ VRCA opened at $4.37 on Friday. Verrica Pharmaceuticals has a twelve month low of $3.28 and a twelve month high of $9.82. The company has a current ratio of 1.45, a quick ratio of 1.33 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $75.07 million, a price-to-earnings ratio of -2.62 and a beta of 1.49. The firm has a 50-day moving average of $5.06 and a two-hundred day moving average of $5.70.

Hedge Funds Weigh In On Verrica Pharmaceuticals

An institutional investor recently raised its stake in Verrica Pharmaceuticals stock. Renaissance Technologies LLC boosted its stake in shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) by 22.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 32,360 shares of the company’s stock after buying an additional 5,960 shares during the period. Renaissance Technologies LLC owned about 0.19% of Verrica Pharmaceuticals worth $171,000 at the end of the most recent reporting period. 42.45% of the stock is owned by institutional investors.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a dermatology-focused pharmaceutical company developing and commercializing treatments for skin diseases. The company’s work centers on topical therapies designed to address conditions for which patients and healthcare providers have limited treatment options.

Verrica’s lead product, YCANTHE (cantharidin) topical solution, 0.7%, is approved by the U.S. Food and Drug Administration for the treatment of molluscum contagiosum in adults and children ages 2 and older.